Literature DB >> 2060149

Effects of antibodies against octreotide in two patients with acromegaly.

H Orskov1, S E Christensen, J Weeke, A Kaal, A G Harris.   

Abstract

Two patients developed specific IgG antibodies against octreotide after 2-3 years' treatment for acromegaly with this long acting somatostatin analogue. The presence of these antibodies reduced the plasma disappearance rate of total extractable octreotide by 60 and 80% respectively. When compared to that of non-immune acromegalic patients, the plasma half-life of octreotide in these two patients was 300 and 450 vs 110 min in those with no detectable octreotide antibodies. The sole observed consequence of the immunization was a marked prolongation of the interval of maximum GH inhibition from a mean of 5 to 8 and 10 h in the two patients described after octreotide injection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060149     DOI: 10.1111/j.1365-2265.1991.tb00311.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 2.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

Review 3.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 4.  Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Authors:  Cassandra Miller; Julie Rousseau; Caterina F Ramogida; Anna Celler; Arman Rahmim; Carlos F Uribe
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.